Compare Cytokinetics Inc (CYTK) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs MobilEye Global Inc — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while MobilEye Global Inc trades at $7.14 (market cap $6.00B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, MobilEye Global Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and MobilEye Global Inc for 15 Days on average.
| CYTK | MBLY | |
|---|---|---|
Market Cap | $8.62B | $6.00B |
Volume | 2,594,626 | 7,007,849 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $15.42 |
52-Week Low | $54.76 | $6.56 |
Typical Hold Time | 19 Days | 15 Days |
Enterprise Value | $8.72B | $4.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Mobileye (MBLY) trades at $7.15, down 4.28% today, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported revenue growth to $1.89B in 2025 but posted a significant net loss of -$392M, with profitability metrics remaining negative. Recent news highlights ADAS business momentum and strategic investments in autonomous mobility, while analyst consensus remains positive with a $10.83 price target.
The stock presents a high-risk opportunity with strong analyst support but persistent profitability challenges. Upside potential exists from autonomous driving adoption and new program ramps, offset by execution risks and negative cash flow projections for 2026. Current valuation below book value offers margin of safety for long-term investors willing to withstand volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
